EGFR and non-small cell lung carcinoma: In a subgroup analysis of the RADIANT trial, erlotinib prolonged DFS (HR, 0.61; 95%CI: 0.38–0.98) but not OS (HR, 1.09; 95%CI: 0.55–2.16) compared to placebo in patients with EGFR-mutant NSCLC.